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Abstract Within the adaptive immune system the transporter
associated with antigen processing (TAP) plays a pivotal role in
loading of peptides onto major histocompatibility (MHC) class I
molecules. As a central tool to investigate the structure and
function of the TAP complex, we created cysteine-less human
TAP subunits by de novo gene synthesis, replacing all 19 cys-
teines in TAP1 and TAP2. After expression in TAP-de¢cient
human ¢broblasts, cysteine-less TAP1 and TAP2 are functional
with respect to adenosine triphosphate (ATP)-dependent peptide
transport and inhibition by ICP47 from herpes simplex virus.
Cysteine-less TAP1 and TAP2 restore maturation and intra-
cellular tra⁄cking of MHC class I molecules to the cell surface.
- 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The translocation of proteasomal proteolytic peptides from
the cytosol into the endoplasmic reticulum (ER) is a crucial
step in antigen processing and presentation to cytotoxic
T-lymphocytes (CTLs). This task is performed by the trans-
porter associated with antigen processing (TAP). In the ER
lumen, these peptides are loaded onto major histocompatibil-
ity (MHC) complex class I molecules and subsequently shut-
tled to the plasma membrane (for review see [1,2]). E⁄cient
peptide loading of MHC class I molecules requires a macro-
molecular loading complex which includes TAP, tapasin,
MHC class I molecules and several other assembling factors
[3,4]. Peptide-loaded MHC complexes are released to the cell
surface, where they are inspected by CTLs, which eventually
lead to lysis/apoptosis of the malignant or infected cell [1].
TAP belongs to the family of ATP-binding cassette (ABC)
transporters that translocate a broad spectrum of solutes
across membranes in an ATP-dependent manner. The TAP
complex located in the ER membrane is a heterodimer com-
prised of TAP1 and TAP2. Each subunit consists of a hydro-
phobic transmembrane domain (TMD) followed by a hydro-
philic conserved cytosolic nucleotide-binding domain (NBD)
(for review see [5,6]). Sequence alignments and hydrophobicity
analyses predict 10 transmembrane helices for human TAP1
and nine for human TAP2 [5]. The N-terminus of TAP1
is most probably directed towards the cytosol, whereas the
N-terminus of TAP2 faces the ER lumen [7].
Both TAP subunits are essential for peptide transport and
no additional factors of the adaptive immune system are re-
quired [8,9]. Consequently, a lack of one TAP subunit leads to
a non-functional transporter and ine⁄cient peptide loading of
MHC class I molecules and their retention in the ER [10^12].
The TAP complex preferentially recognizes peptides of 8^16
amino acids [13]. The transport mechanism by TAP can be
divided into two basic steps: ATP-independent peptide bind-
ing and ATP-dependent peptide translocation across the ER
membrane [5,13,14].
The interdependency between peptide binding, transport
and release, its synchronization with ATP binding and hydro-
lysis have been recently investigated [15^18]. However, many
questions concerning structure, dynamics and mechanism of
the TAP complex remain open. Cysteine-less TAP mutants
will be a powerful tool to address these topics [19]. Applying
cysteine-scanning mutagenesis, the membrane topology and
dynamic crosstalk between both NBDs and TMDs can be
analyzed while preserving function and topology of the trans-
porter investigated.
In this study, we report the de novo gene synthesis and
functional expression of cysteine-less TAP1 and TAP2 sub-
units. In vitro transport assays demonstrate that cysteine-
less and wild-type TAP1 and TAP2 are functionally equiva-
lent with regard to ATP-dependent peptide translocation into
the ER and inhibition by the herpes viral inhibitor ICP47. We
were able to restore TAP-dependent peptide transport in vivo
and to induce upregulation of MHC class I expression at the
cell surface by transfection of cysteine-less TAP1 and TAP2 in
TAP-de¢cient human skin ¢broblasts.
2. Materials and methods
2.1. De novo synthesis of the cysteine-less TAP1 and TAP2
Partially overlapping oligonucleotides (60 bp in length and 15 bp
overlap at both ends) were synthesized (Syngen-Biotech, Munich,
Germany). Five double-stranded DNA fragments (400^450 bp) of
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each TAP subunit were generated by polymerase chain reactions. The
DNA fragments were cloned into the vector pCR-Script (Stratagene)
and sequenced. By using unique restriction sites, the fragments were
assembled to the complete cDNA coding for cysteine-less TAP1 and
TAP2. Finally, de novo genes were subcloned into the expression
vector p46 (pCMVires Neo-derivative) and con¢rmed by sequencing.
De novo tap1 and tap2 were constructed with a C-terminal His10-
tag and Strep0-tag, respectively. The plasmids were named as
p46.TAP1dn and p46.TAP2dn. In addition, wild-type tap1 and tap2
were cloned into the expression vector p46.
2.2. Cell lines and culture
TAP1-de¢cient BRE cells (BRE.TAP13/3) and TAP2-de¢cient
STF cells (STF.TAP23/3) were kindly provided by Henri de la Salle
[12] and maintained in Dulbecco’s modi¢ed Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine,
100 Wg/ml streptomycin and 100 U/ml penicillin.
2.3. Stable transfection of TAP-de¢cient cells
24 h after plating of 1U105 BRE.TAP13/3 and STF.TAP23/3
cells, the cells were transfected with 0.5 Wg of linearized plasmid DNA
(p46.TAP1dn or p46.TAP1wt and p46.TAP2dn or p46.TAP2wt) using
the E¡ectene Transfection Kit (Qiagen). Cells were selected in
DMEM (see Section 2.2) supplemented with 100 Wg/ml hygromycin
B and 500 Wg/ml G418. The medium was exchanged every second day.
After 5^6 weeks, G418-resistant positive cell clones were isolated and
expanded for further analysis. Stable BRE transfectants were named
as BRE.TAP1dn or BRE.TAP1wt, stable STF transfectants were in-
dicated as STF.TAP2dn or STF.TAP2wt.
2.4. Membrane preparation and Western blot analysis
Approximately 1U107 cells were resuspended in 10 mM Tris bu¡er
(pH 8.0) containing 1 mM dithiothreitol, 10 Wg/ml aprotinin, 9.5 Wg/Wl
leupeptin, 17 Wg/Wl pepstatin, 50 Wg/ml phenylmethylsulfonyl £uoride
and 10 Wg/ml trypsin inhibitor and homogenized with a tight glass
Dounce homogenizer (Braun, Melsungen, Germany). Cell debris was
removed by centrifugation at 1000Ug for 10 min at 4‡C. The super-
natant was subsequently centrifuged at 200 000Ug for 40 min at 4‡C.
Proteins of the membrane fraction were separated by sodium dodecyl
sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) (9%) and an-
alyzed by immunoblotting. TAP1 was detected by enhanced chemilu-
minescence (ECL) using mAb148.3 [8] and a peroxidase-conjugated
anti-mouse antibody (Sigma-Aldrich).
2.5. Peptide transport assay
The peptide RRYQNSTEL was labeled with 125I by chloramine T
as previously described [8]. 2.5U106 cells were semi-permeabilized
with 0.05% (w/v) saponin in 50 Wl transport bu¡er (20 mM HEPES,
130 mM KCl, 10 mM NaCl, 1 mM CaCl2, 2 mM ethyleneglycol-
bis-(L-aminoethylether)-N,N,NP,NP-tetraacetic acid (EGTA), 2 mM
MgCl2, pH 7.3) for 1 min at room temperature and subsequently
diluted in 1 ml of transport bu¡er, centrifuged and washed with trans-
port bu¡er. The peptide transport assay was started by adding 10 mM
ATP and 0.8 WM of radiolabeled peptide in a ¢nal volume of 100 Wl.
After incubation at 37‡C for 20 min, the cells were lysed in lysis bu¡er
(50 mM Tris, 150 mM NaCl, 5 mM KCl, 1 mM CaCl2, 2 mM MnCl2,
1% IGEPAL, pH 7.5). The N-core glycosylated and therefore trans-
ported peptides were recovered with concanavalin A (ConA)-Sepha-
rose beads (Sigma-Aldrich) overnight at 4‡C [20]. After washing in
lysis bu¡er, ConA-bound radiolabeled peptides were quanti¢ed by
Q-counting.
2.6. Flow cytometry
MHC class I surface expression was monitored by £uorescence-
activated cell sorting (FACS) analysis. 5U105 cells were harvested,
washed twice with phosphate-bu¡ered saline (PBS), and then incuba-
ted for 30 min on ice with the antibody HLA-ABC-FITC (Beckman/
Coulter), which is speci¢c for all MHC class I subtypes. For isotypic
control, cells were incubated with the antibody IgG2a-FITC (Beck-
man/Coulter). After washing with PBS, 5000 viable cells were ana-
lyzed by £ow cytometry (Coulter Epics XL MCL using System II 3.0;
Beckman/Coulter).
3. Results and discussion
3.1. Cloning of cysteine-less TAP subunits and generation of
stable transfectants
To create cysteine-less human TAP, the tap genes were syn-
thesized by partially overlapping oligonucleotides and PCR
reactions as described in Section 2. By using unique restriction
sites ¢ve PCR fragments were assembled to the complete de
novo tap1 (2298 bp, C-terminal His10-tag) and de novo tap2
sequence (2163 bp, C-terminal Strep0-tag). All cysteines, nine
of TAP1 and 10 of TAP2, were replaced by de novo gene
synthesis and assembly (Fig. 1). Cysteines were substituted
Fig. 1. Structural organization of the human TAP complex. The membrane helices are predicted from hydrophobicity analysis and sequence
alignment with human MDR1 [5]. The N-terminal domain (N-domain) and the classical six-helix motif found in most ABC transporters of the
TMD are illustrated in light and dark gray cylinders, respectively. The NBD consists of the highly conserved Walker A and B motifs (A, B)
and the C-loop (C). Dashed lines illustrate the peptide-binding region as identi¢ed by photo-cross-linking experiments [23]. Asterisks indicate
the location of the nine and 10 cysteines within TAP1 and TAP2, respectively.
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by serines (C6S, C12S, C14S, C73S, C179S, C488S, C662S,
C735S of TAP1; C70S, C213S, C353S, C363S, C571S, C641S
of TAP2); however, cysteines located within predicted trans-
membrane helices were exchanged to alanines (C315A of
TAP1; C197A, C209A of TAP2). Based on sequence align-
ments among TAP homologs from other species, two cys-
teines in TAP2 were replaced by histidine and valine
(C394V and C540H). It should be stressed that none of the
cysteines is conserved within TAP proteins from other species.
Furthermore, based on the predicted membrane topology, no
cysteine residue is located in the ER lumen, which could be
involved in disul¢de formation. By introducing unique restric-
tion sites via silent mutations, de novo tap1 and tap2 were
subdivided into gene cassettes of 150^250 bp each, which can
easily be mutagenized and exchanged. In addition, the codon
usage of the de novo tap1 and tap2 was optimized for expres-
sion in Escherichia coli, Saccharomyces cerevisiae and mam-
malian cells.
De novo (cysteine-less) and wild-type tap1 or tap2 were
cloned into the expression vector p46 and transfected into
human skin ¢broblasts, BRE.TAP13/3 or STF.TAP23/3,
lacking TAP1 or TAP2 expression, respectively [12]. Genomic
integration of the de novo tap1 and tap2 genes leading to
G418-resistant BRE.TAP1dn or STF.TAP2dn cell lines was
proven by genomic PCR (data not shown). For control ex-
periments, wild-type TAP1 or TAP2 transfectants of both
TAP-de¢cient cell lines were generated (BRE.TAP1wt or
STF.TAP2wt).
Fig. 2. Expression of cysteine-less TAP1. Proteins (30 Wg/lane) ob-
tained from membrane preparation of T1, BRE.TAP13/3, BRE.-
TAP1wt and BRE.TAP1dn cells were separated by SDS^PAGE
(9%), blotted onto a nitrocellulose membrane, probed with the anti-
hTAP1 mAb148.3 [8] and visualized by means of ECL detection re-
agent.
Fig. 3. ATP-dependent peptide transport by cysteine-less TAP1 and TAP2. The translocation assay was performed with 0.8 WM I125-labeled
peptide (RRYQNSTEL) for 20 min at 37‡C in presence (dark bars) and absence of 10 mM MgATP (open bars) using 2.5U106 saponin semi-
permeabilized BRE.TAP13/3, BRE.TAP1wt, BRE.TAP1dn (A), as well as STF.TAP23/3, STF.TAP2wt and STF.TAP2dn cells (B). The
transported and glycosylated peptides (ConA-bound) were quanti¢ed by Q-counting. Similar in vitro transport assays were performed in the
presence of a competitor peptide (160 WM of RRYQNSTEL, dashed bars) or the viral TAP inhibitor ICP47 (20 WM, gray bars) with BRE.
TAP1dn (C) and STF.TAP2dn transfectants (D). Error bars indicate the deviation of two independent experiments.
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Expression of cysteine-less and wild-type TAP1 was dem-
onstrated by SDS^PAGE and Western blot analysis using the
monoclonal antibody 148.3 directed against the C-terminus of
human TAP1 [8]. In membrane preparations of all BRE trans-
fectants and T1 cells (positive control), TAP1 was detected at
the expected size of 71 kDa, whereas the parental BRE.
TAP13/3 cell line showed no TAP1 expression (Fig. 2). De
novo and wild-type TAP1 show the same apparent molecular
mass.
Expression of cysteine-less and wild-type TAP2 was ana-
lyzed in STF cells using the monoclonal antibody 429.3 spe-
ci¢c for human TAP2 [13]. However, TAP2 appears to be
expressed at very low level in transfected STF.TAP2wt and
STF.TAP2dn cells and could therefore not be detected. The
immune detection of TAP2 could not be improved by using
other monoclonal or polyclonal antibodies. Even though
TAP2 expression is limiting for the formation of TAP1/
TAP2 heterodimers, the amount of functional transporters is
su⁄cient to be detected in assays addressing peptide transport
and restoration of MHC class I surface expression (see be-
low).
3.2. Function of cysteine-less TAP1 and TAP2
The intracellular transport of peptides into the ER lumen is
a central step in antigen processing. To investigate whether
the substitution of cysteines has an e¡ect on TAP function, in
vitro peptide transport assays were performed with saponin
semi-permeabilized BRE and STF ¢broblasts. ATP-dependent
transport of the radiolabeled peptide (RRYQNSTEL) into the
ER was analyzed in the presence and absence of ATP. After
cell lysis, transported and N-core glycosylated peptides were
quanti¢ed by Q-counting. As shown in Fig. 3A, ATP-depen-
dent peptide transport was restored in cysteine-less and wild-
type TAP1 transfectants (BRE.TAP1dn and BRE.TAP1wt),
whereas no speci¢c transport activity was observed in parental
BRE.TAP13/3 ¢broblasts. The transport e⁄ciencies of the
TAP complex comprising wild-type and de novo TAP1 were
comparable, indicating that the replacement of all nine cys-
teines within the TAP1 had no e¡ect on TAP transport func-
tion.
ATP-dependent peptide translocation was also observed for
de novo and wild-type TAP2 transfectants, indicating that the
exchange of 10 cysteines within TAP2 did not interfere with
TAP transport function (Fig. 3B). We did not detect speci¢c
transport activity in case of the TAP2-de¢cient cell line
(STF.TAP23/3). Similar results were obtained for several
clones of tap1 or tap2 transfectants.
Next, we analyzed whether the exchange of cysteines in
human TAP1 or TAP2 a¡ects the high-a⁄nity interaction
with ICP47 from herpes simplex virus, which speci¢cally
blocks peptide binding and translocation by human TAP
[21,22]. As shown in Fig. 3C and D, ICP47 speci¢cally blocks
peptide translocation of cysteine-less TAP1 and TAP2. Sim-
ilar inhibition was achieved by a 200-fold excess of unlabeled
peptide. In summary, exchange of all 19 cysteines in both
TAP subunits maintains TAP function as well as sensitivity
towards the viral inhibitor ICP47.
3.3. Restoration of MHC class I surface expression by
cysteine-less TAP1 and TAP2
After translocation of peptides into the ER lumen and sub-
sequent loading onto MHC class I molecules, the peptide^
MHC complexes are shuttled to the plasma membrane.
Thus, the level of MHC class I surface expression serves as
a readout for a functional antigen processing machinery. To
analyze whether cysteine-less TAP subunits can restore matu-
ration and intracellular tra⁄cking of MHC I complexes, we
determined the surface expression of MHC class I molecules
by FACS analysis. The speci¢c £uorescence intensity for
Fig. 4. Restoration of MHC class I surface expression by cysteine-
less TAP1 and TAP2. To analyze antigen processing in BRE.
TAP13/3, BRE.TAP1wt, BRE.TAP1dn (A) as well as STF.
TAP23/3, STF.TAP2wt and STF.TAP2dn cell lines (B), the MHC
class I expression on the cell surface was studied by FACS analysis
using the anti-MHC class I antibody HLA-ABC-FITC. The anti-
body IgG2a-FITC was used for isotopic control (white graph). One
representative experiment out of at least two independent measure-
ments for each cell line is shown.
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transfected BRE.TAP1wt cells was determined to be 59.3,
which is characteristic for a functional and e⁄cient pathway
of antigen presentation (Fig. 4A). Furthermore, MHC class I
surface expression was shown for the cysteine-less TAP-trans-
fected BRE cells with a higher £uorescence intensity of 147.5
when compared to the BRE.TAP1wt cell line. As expected the
parental TAP1-de¢cient BRE cells showed largely suppressed
MHC class I surface expression (log £uorescence intensity
3.3).
Similarly, the TAP2-transfected STF cell lines were ana-
lyzed by FACS. The speci¢c £uorescence intensity for the
STF.TAP2wt cell line was determined to be 14.7, whereas
the cysteine-less TAP2 transfectants displayed a marginally
lower speci¢c £uorescence intensity of 12.1 (Fig. 4B). The
parental TAP2-de¢cient STF cells showed strongly reduced
MHC class I surface expression (log £uorescence intensity
4.4).
In summary, we show that the replacement of all cysteines
within TAP1 and TAP2 has no e¡ect on peptide transport,
maturation and intracellular tra⁄cking of MHC class I mol-
ecules to the cell surface. We therefore conclude that both
cysteine-less TAP subunits preserve their functionality as
key players in the pathway of antigen presentation. Cys-
teine-less TAP is an important tool and prerequisite for the
investigation of structure, dynamics and transport mechanism
of TAP as well as the overall organization of the macromo-
lecular MHC loading complex.
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